A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.

<h4>Background</h4>The immunosuppressive agents mycophenolate acid (MPA) and tacrolimus (Tac) are associated with a higher incidence of BK polyomavirus nephropathy (BKPyVAN). In this observational retrospective cohort study, the frequency of BK polyomavirus (BKPyV) complications over a 2...

Full description

Saved in:
Bibliographic Details
Main Authors: Lilli Gard, Willem van Doesum, Hubert G M Niesters, Willem J van Son, Arjan Diepstra, Coen A Stegeman, Henk Groen, Annelies Riezebos-Brilman, Jan Stephan Sanders
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178801&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849715588181524480
author Lilli Gard
Willem van Doesum
Hubert G M Niesters
Willem J van Son
Arjan Diepstra
Coen A Stegeman
Henk Groen
Annelies Riezebos-Brilman
Jan Stephan Sanders
author_facet Lilli Gard
Willem van Doesum
Hubert G M Niesters
Willem J van Son
Arjan Diepstra
Coen A Stegeman
Henk Groen
Annelies Riezebos-Brilman
Jan Stephan Sanders
author_sort Lilli Gard
collection DOAJ
description <h4>Background</h4>The immunosuppressive agents mycophenolate acid (MPA) and tacrolimus (Tac) are associated with a higher incidence of BK polyomavirus nephropathy (BKPyVAN). In this observational retrospective cohort study, the frequency of BK polyomavirus (BKPyV) complications over a 24-month period was studied.<h4>Methods</h4>358 renal transplant recipients (RTR) treated with MPA, with either cyclosporine A (CsA) (CsAM group) or Tac (TacM group) and mostly prednisolone, were included.<h4>Results</h4>Incidence of BKPyV-viremia was not significantly different between the CsAM (n = 42/191) (22.0%) and the TacM (n = 36/167) (21.6%) group. Biopsy proven BKPyVAN occurred more often in the TacM group (6.6%) versus the CsAM group (2.1%) (p = 0.03). Longitudinal data analysis showed a significant earlier decline of viral load in plasma in the CsAM group compared to the TacM group (p = 0.005). The incidence of biopsy proven acute rejection (BPAR) was significantly higher in the CsAM (19.9%) compared to the TacM (10.8%) (p = 0.02) group. Graft loss, estimated glomerular filtration rate and mortality rate did not differ in both treatment groups.<h4>Conclusion</h4>In conclusion, this study shows that immunosuppressive treatment with Tac and MPA compared to CsA and MPA is associated with a lower incidence of BPAR, but at the cost of an increased risk of developing BKPyVAN in the first two years post-transplant.
format Article
id doaj-art-6d0712e5346e434b9535e6ba96a8b08c
institution DOAJ
issn 1932-6203
language English
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-6d0712e5346e434b9535e6ba96a8b08c2025-08-20T03:13:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01126e017880110.1371/journal.pone.0178801A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.Lilli GardWillem van DoesumHubert G M NiestersWillem J van SonArjan DiepstraCoen A StegemanHenk GroenAnnelies Riezebos-BrilmanJan Stephan Sanders<h4>Background</h4>The immunosuppressive agents mycophenolate acid (MPA) and tacrolimus (Tac) are associated with a higher incidence of BK polyomavirus nephropathy (BKPyVAN). In this observational retrospective cohort study, the frequency of BK polyomavirus (BKPyV) complications over a 24-month period was studied.<h4>Methods</h4>358 renal transplant recipients (RTR) treated with MPA, with either cyclosporine A (CsA) (CsAM group) or Tac (TacM group) and mostly prednisolone, were included.<h4>Results</h4>Incidence of BKPyV-viremia was not significantly different between the CsAM (n = 42/191) (22.0%) and the TacM (n = 36/167) (21.6%) group. Biopsy proven BKPyVAN occurred more often in the TacM group (6.6%) versus the CsAM group (2.1%) (p = 0.03). Longitudinal data analysis showed a significant earlier decline of viral load in plasma in the CsAM group compared to the TacM group (p = 0.005). The incidence of biopsy proven acute rejection (BPAR) was significantly higher in the CsAM (19.9%) compared to the TacM (10.8%) (p = 0.02) group. Graft loss, estimated glomerular filtration rate and mortality rate did not differ in both treatment groups.<h4>Conclusion</h4>In conclusion, this study shows that immunosuppressive treatment with Tac and MPA compared to CsA and MPA is associated with a lower incidence of BPAR, but at the cost of an increased risk of developing BKPyVAN in the first two years post-transplant.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178801&type=printable
spellingShingle Lilli Gard
Willem van Doesum
Hubert G M Niesters
Willem J van Son
Arjan Diepstra
Coen A Stegeman
Henk Groen
Annelies Riezebos-Brilman
Jan Stephan Sanders
A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.
PLoS ONE
title A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.
title_full A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.
title_fullStr A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.
title_full_unstemmed A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.
title_short A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients.
title_sort delicate balance between rejection and bk polyomavirus associated nephropathy a retrospective cohort study in renal transplant recipients
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178801&type=printable
work_keys_str_mv AT lilligard adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT willemvandoesum adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT hubertgmniesters adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT willemjvanson adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT arjandiepstra adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT coenastegeman adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT henkgroen adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT anneliesriezebosbrilman adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT janstephansanders adelicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT lilligard delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT willemvandoesum delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT hubertgmniesters delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT willemjvanson delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT arjandiepstra delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT coenastegeman delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT henkgroen delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT anneliesriezebosbrilman delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients
AT janstephansanders delicatebalancebetweenrejectionandbkpolyomavirusassociatednephropathyaretrospectivecohortstudyinrenaltransplantrecipients